Kelly A Dougherty1, Joan I Schall2, Babette S Zemel1, Florin Tuluc3, Xiaoling Hou4, Richard M Rutstein5, Virginia A Stallings1. 1. Division of Gastroenterology, Hepatology, and Nutrition, University of Pennsylvania Perelman School of Medicine, Children's Hospital of Philadelphia, Pennsylvania. 2. Division of Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Pennsylvania. 3. Division of Allergy/Immunology, Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Children's Hospital of Philadelphia, Pennsylvania. 4. University of Pennsylvania Perelman School of Medicine, Center for Clinical Epidemiology and Biostatistics, Biostatistics Analysis Center, Philadelphia, Pennsylvania. 5. Division of General Pediatrics, Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Children's Hospital of Philadelphia, Pennsylvania.
Abstract
BACKGROUND:Suboptimal vitamin D (vitD) status is common in children and young adults infected with human immunodeficiency virus (HIV). The vitD supplemental dose needed to normalize vitD status in this population is unknown. METHODS: In this double-blind trial, subjects infected with HIV ages 8.3 to 24.9 years were randomized to vitD3 supplementation of 4000 IU/day or 7000 IU/day and evaluated at 6 and 12 week for changes in vitD status and HIV indicators. A dose was considered unsafe if serum calcium was elevated (above age and sex-specific range) associated with elevated serum 25 hydroxyvitamin D (25(OH)D); >160 ng/mL). RESULTS: At baseline, 95% of subjects (n = 44; 43% with perinatally acquired HIV, 57% with behaviorally acquired HIV) had a suboptimal serum 25(OH)D concentration of <32 ng/mL (mean ± standard deviation, 19.3 ± 7.4; range, 4.4-33.6 ng/mL). After 12 weeks (main outcome) of D3 supplementation, both D3 doses were safe and well tolerated, with no evidence of elevation of serum calcium concentrations or deterioration in HIV immunologic or virologic status. Sufficient vitD status, defined as serum 25(OH)D ≥32 ng/mL, was achieved in 81% of all subjects, and only the 7000 IU/day group (86%) achieved this a priori efficacy criterion in >80% of subjects. Change in serum 25(OH)D did not differ between HIV acquisition groups. CONCLUSIONS: A 7000 IU/day D3 supplementation was safe and effective in children and young adults infected with HIV.
RCT Entities:
BACKGROUND: Suboptimal vitamin D (vitD) status is common in children and young adults infected with human immunodeficiency virus (HIV). The vitD supplemental dose needed to normalize vitD status in this population is unknown. METHODS: In this double-blind trial, subjects infected with HIV ages 8.3 to 24.9 years were randomized to vitD3 supplementation of 4000 IU/day or 7000 IU/day and evaluated at 6 and 12 week for changes in vitD status and HIV indicators. A dose was considered unsafe if serum calcium was elevated (above age and sex-specific range) associated with elevated serum 25 hydroxyvitamin D (25(OH)D); >160 ng/mL). RESULTS: At baseline, 95% of subjects (n = 44; 43% with perinatally acquired HIV, 57% with behaviorally acquired HIV) had a suboptimal serum 25(OH)D concentration of <32 ng/mL (mean ± standard deviation, 19.3 ± 7.4; range, 4.4-33.6 ng/mL). After 12 weeks (main outcome) of D3 supplementation, both D3 doses were safe and well tolerated, with no evidence of elevation of serum calcium concentrations or deterioration in HIV immunologic or virologic status. Sufficient vitD status, defined as serum 25(OH)D ≥32 ng/mL, was achieved in 81% of all subjects, and only the 7000 IU/day group (86%) achieved this a priori efficacy criterion in >80% of subjects. Change in serum 25(OH)D did not differ between HIV acquisition groups. CONCLUSIONS: A 7000 IU/day D3 supplementation was safe and effective in children and young adults infected with HIV.
Authors: Jong Hun Kim; Vani Gandhi; George Psevdos; Fabiola Espinoza; Joyce Park; Victoria Sharp Journal: AIDS Res Hum Retroviruses Date: 2011-07-06 Impact factor: 2.205
Authors: Tanya Welz; Kate Childs; Fowzia Ibrahim; Mary Poulton; Chris B Taylor; Caje F Moniz; Frank A Post Journal: AIDS Date: 2010-07-31 Impact factor: 4.177
Authors: Kelly A Dougherty; Joan I Schall; Alisha J Rovner; Virginia A Stallings; Babette S Zemel Journal: J Pediatr Hematol Oncol Date: 2011-03 Impact factor: 1.289
Authors: Camille E Powe; Catherine Ricciardi; Anders H Berg; Delger Erdenesanaa; Gina Collerone; Elizabeth Ankers; Julia Wenger; S Ananth Karumanchi; Ravi Thadhani; Ishir Bhan Journal: J Bone Miner Res Date: 2011-07 Impact factor: 6.741
Authors: Giuseppe Saggese; Francesco Vierucci; Flavia Prodam; Fabio Cardinale; Irene Cetin; Elena Chiappini; Gian Luigi De' Angelis; Maddalena Massari; Emanuele Miraglia Del Giudice; Michele Miraglia Del Giudice; Diego Peroni; Luigi Terracciano; Rino Agostiniani; Domenico Careddu; Daniele Giovanni Ghiglioni; Gianni Bona; Giuseppe Di Mauro; Giovanni Corsello Journal: Ital J Pediatr Date: 2018-05-08 Impact factor: 2.638
Authors: Virginia A Stallings; Joan I Schall; Mary L Hediger; Babette S Zemel; Florin Tuluc; Kelly A Dougherty; Julia L Samuel; Richard M Rutstein Journal: Pediatr Infect Dis J Date: 2015-02 Impact factor: 2.129
Authors: J C Brown; J I Schall; R M Rutstein; M B Leonard; B S Zemel; V A Stallings Journal: J Musculoskelet Neuronal Interact Date: 2015-06 Impact factor: 2.041
Authors: Andrew P Steenhoff; Joan I Schall; Julia Samuel; Boitshepo Seme; Marape Marape; Bakgaki Ratshaa; Irene Goercke; Michael Tolle; Maria S Nnyepi; Loeto Mazhani; Babette S Zemel; Richard M Rutstein; Virginia A Stallings Journal: PLoS One Date: 2015-02-23 Impact factor: 3.240
Authors: Justin Penner; Rashida A Ferrand; Ceri Richards; Kate A Ward; James E Burns; Celia L Gregson Journal: PLoS One Date: 2018-11-15 Impact factor: 3.240
Authors: Rbab Taha; Shahd Abureesh; Shuruq Alghamdi; Rola Y Hassan; Mohamed M Cheikh; Rania A Bagabir; Hani Almoallim; Altaf Abdulkhaliq Journal: Int J Gen Med Date: 2021-07-24